Indi Molecular is developing protein catalyzed capture agents (PCCs) as a small molecule replacement for antibodies in in vivo imaging, therapeutics, and in vitro diagnostics. The PCC platform allows us to build fully synthetic small peptides against specific epitopes of the desired target protein. Affinity and specificity are equivalent or superior to monoclonal antibodies.
We’ve even achieved picomolar binding affinities. PCCs are the synthetic equivalent of monoclonal antibodies, offering the small size (< 4 kD) and biophysical properties of a small molecule drug.
Specific to the chosen epitope of the desired target protein
Pico-molar and low nano-molar binding affinities
Fully synthetic small peptides for rapid and robust manufacturing